Perinatal exposure to CNS-active medications: Neurodevelopmental risks

CNS Drugs

Volumn 12, Issue 6, 1999, Pages 451-470

  Simar, M Renée ^a,b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

BRAIN MATURATION; DRUG SAFETY; HUMAN; LACTATION; MEDICAL DECISION MAKING; MOTOR DEVELOPMENT; NERVE CELL DIFFERENTIATION; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENESIS; TREATMENT PLANNING;

EID: 0033385404     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912060-00004     Document Type: Review

References (213)

1. 1. Steiner M. Perinatal mood disorders: position paper. Psychopharmacol Bull 1998; 34 (3): 301-6
2. 2. Reynolds F. The effects on the infant of psychotropic drugs used in pregnancy. In: Krauer B, Krauer F, Hytten FE, et al., editors. Drugs and pregnancy: maternal drug handling - fetal drug exposure. New York (NY): Academic Press, 1984
3. 3. Dencker L, Danielsson BRG. Transfer of drugs to the embryo and fetus after placentation. In: Nau H, Scott Jr WJ, editors. Interspecies comparison and maternal/embryonic-fetal drug transfer. Boca Raton (FL): CRC Press, Inc., 1987: 55-69
4. 4. Watanabe T, Matsuhashi K, Takayama S. Placental and blood-brain barrier transfer following prenatal and postnatal exposures to neuroactive drugs: relationships with partition coefficient and behavioral teratogenesis. Toxicol Appl Pharmacol 1990; 105: 66-77
5. 5. Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980; 5: 1-66
6. 6. Pons G, Rey E, Matheson I. Excretion of psychoactive drugs in breast milk: pharmacokinetic principles and recommendations. Clin Pharmacokinet 1994; 27 (4): 270-89
7. 7. Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59 Suppl. 2: 53-61
8. 8. Kilpatrick CJ, Moulds RFW. Anticonvulsants in pregnancy. Med J Aust 1991; 154: 199-202
9. 9. Robins L, Mills J. Effects of in utero exposure to street drugs. Am J Public Health 1993; 83 Suppl.: 9-31
10. 10. Wetherington CL, Smeriglio VL, Finnegan LP, editors. Behavioral studies of drug-exposed offspring: methodological issues in human and animal research. Rockville (MD): National Institute on Drug Abuse, 1996
11. 11. Werboff J, Gottlieb JS. Drugs in pregnancy: behavioral teratology. Obstet Gynecol Surv 1963; 118: 420-3
12. 12. Schmidt RR, Johnson EM. Principles of teratology. In: Hood RD, editor. Handbook of developmental toxicology. New York (NY): CRC Press, 1997: 3-12
13. 13. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153 (5): 592-606
14. 14. Miller LJ. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 1991; 9 (2): 275-98
15. 15. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry 1998; 59 (2): 41-51
16. 16. Committee on Drugs American Academy of Pediatrics. Psychotropic drugs in pregnancy and lactation. Pediatrics 1982; 69: 241-4
17. 17. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93 (2): 138-50
18. 18. Chang LW, Slikker W, editors. Neurotoxicology: approaches and methods. San Diego (CA): Academic Press, 1995
19. 19. Hood RD, editor. Handbook of developmental toxicology. Boca Raton (FL): CRC Press, 1997
20. 20. Riley EP, Vorhees CV, editors. Handbook of behavioral teratology. New York (NY): Plenum, 1986
21. 21. Yanai J, editor. Neurobehavioral teratology. Amsterdam: Elsevier, 1984
22. 22. Hutchings DE. Issues of methodology and interpretation in clinical and animal behavioral teratology studies. Neurobehav Toxicol Teratol 1985; 7: 639-42
23. 23. Rodier PM. Chronology of neuron development: animal studies and their clinical implications. Dev Med Child Neurol 1980; 22: 525-45
24. 24. Bayer SA, Altman J, Russo RJ, et al. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 1993; 14 (1): 83-144
25. 25. Purves D, Lichtman JW. Principles of neural development. Sunderland (MA): Sinauer Associates Inc., 1985: 25-51
26. 26. Levitt P, Harvey JA, Friedman E, et al. New evidence for neurotransmitter influences on brain development. Trends Neurosci 1997; 20 (6): 269-74
27. 27. Leonard BE. Fundamentals of psychopharmacology. New York (NY): John Wiley & Sons, 1992: 1-46
28. 28. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957; 12: 323-8
29. 29. Baskys A, Remington G. Serotonin and dopamine as neurotransmitters. In: Baskys A, Remington G, editors. Brain mechanisms and psychotropic drugs. Boca Raton (FL): CRC Press, 1996: 55-71
30. 30. Gu Q, Singer W. Involvement of serotonin in developmental plasticity of kitten visual cortex. Eur J Neurosci 1995; 7 (6): 1146-53
31. 31. Dinopoulos A, Dori I, Parnavelas JG. The serotonin innervation of the basal forebrain shows a transient phase during development. Brain Res Cogn Res 1997; 99: 38-52
32. 32. Lauder JM, Wallace JA, Krebs H, et al. In vivo and in vitro development of serotonergic neurons. Brain Res Bull 1982; 9: 605-25
33. 33. Holson RR, Webb PJ, Grafton TF, et al. Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms. Teratology 1994; 50: 122-36
34. 34. Felten DL, Hallman H, Jonsson G. Evidence for a neurotrophic role of noradrenaline neurons in the postnatal development of rat cerebral cortex. J Neurocytol 1982; 11: 119-35
35. 35. Pappas BA, Peters DA, Sobrian AK, et al. Early behavioral and catecholaminergic effects of 6-hydroxydopamine and guanethidine in the neonatal rat. Pharmacol Biochem Behav 1975; 3 (4): 681-5
36. 36. Cases O, Seif I, Grimsby J, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995; 268: 1763-6
37. 37. Lauder JM, Krebs H. Neurotransmitters in development as possible substrates for drugs of use and abuse. In: Yanai J, editor. Neurobehavioral teratology. Amsterdam: Elsevier, 1984: 289-314
38. 38. Levitt P, Reinoso B, Jones L. The critical impact of early cellular environment on neuronal development. Prev Med 1998; 27 (2): 180-3
39. 39. Morilak DA, Porteus MH, Ciaranello RD. Molecular and cellular mechanisms of brain development. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology. 4th ed. New York (NY): Raven Press, 1995: 671-81
40. 40. Swaab DF. Relation between maturation of neurotransmitter systems in the human brain and psychosocial disorders. In: Rutter M, Casaer P, editors. Biological risk factors for psychosocial disorders. Cambridge: Cambridge University Press, 1991: 50-66
41. 41. Patel AJ, Barochovsky O, Lewis PD. Psychotropic drugs and brain development: effects on cell replication in vivo and in vitro. Neuropharmacology 1981; 20: 1243-9
42. 42. Coyle I, Wayner MJ, Singer G. Behavioral teratogenesis: a critical evaluation. Pharmacol Biochem Behav 1976; 4: 191-200
43. 43. Skalko RG. Pharmacological concepts and developmental toxicology. In: Hutchings SE, editor. Prenatal abuse of licit and illicit drugs. New York (NY): New York Academy of Sciences, 1989: 21-30
44. 44. Vorhees CV. Concepts in teratology and developmental toxicology derived from animal research. In: Hutchings SE, editor. Prenatal abuse of licit and illicit drugs. New York (NY): New York Academy of Sciences, 1989: 31-41
45. 45. Cagiano R, Barfield RJ, White NR, et al. Subtle behavioural changes produced in rat pups by in utero exposure to haloperidol. Eur J Pharmacol 1988; 157 (1): 45-50
46. 46. Cagiano R, Sales GD, Renna G, et al. Ultrasonic vocalization in rat pups: effects of early postnatal exposure to haloperidol. Life Sci 1986; 38 (15): 1417-23
47. 47. Dobbing J, Sands J. Quantitative growth and development of human brain. Arch Dis Child 1973; 48 (10): 757-67
48. 48. Gadson DR, Emery JL. Some quantitative morphological aspects of post-natal human cerebellar growth. J Neurol Sci 1976; 29: 137-48
49. 49. Buelke-Sam J, Kimmel CA. Developmental and standardization of screening methods for behavioral teratology. Teratology 1979; 20: 17-30
50. 50. Altshuler LL, Szuba MP. Course of psychiatric disorders in pregnancy: dilemmas in pharmacologic management. Neurol Clin 1994; 12 (3): 613-35
51. 51. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry 1984; 25 (1): 32-7
52. 52. Rumeau-Rouguette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977; 15 (57-64): 57-64
53. 53. Wier PJ. Neurobehavioral evaluations: integral components of developmental toxicity testing. In: Weiss B, O'Donoghue J, editors. Neurobehavioral toxicity: analysis and interpretation. New York (NY): Raven Press, Ltd, 1994: 71-82
54. 54. Auroux M. Behavioral teratogenesis: an extension to the teratogenesis of functions. Biol Neonate 1997; 71: 137-47
55. 55. Riley EP, Hannigan JH, Balaz-Hannigan MA. Behavioral teratology as the study of early brain damage: considerations for the assessment of neonates. Neurohehav Toxicol Teratol 1985; 7: 635-8
56. 56. Spear LP. Drug-vulnerable events in neuronal development: implications for the selection of test methodologies. In: Friedman DP, Clouet DH, editors. NIDA research monograph series: the role of neuroplasticity in the response to drugs. Rockville (MD): National Institute on Drug Abuse, 1987: 30-45
57. 57. Eckerman DA, Bushnell PJ. The neurotoxicology of cognition: attention, learning, and memory. In: Tilson H, Mitchell C, editors. Neurotoxicology. New York (NY): Raven Press, 1992: 213-70
58. 58. Ba A, Seri BV. Psychomotor functions in developing rats: ontogenetic approach to structure-function relationships. Neurosci Biobehav Rev 1995; 19 (3): 413-25
59. 59. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995; 7: 220-33
60. 60. Lauder JM. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 1993; 16 (6): 233-40
61. 61. Rosengarten H, Friedhoff AJ. Enduring changes in dopamine receptor cells of pups from drug administration to pregnant and nursing rats. Science 1979; 203 (16): 1133-5
62. 62. Spear LP. Age at the time of testing reconsidered in neurobehavioral teratological research. In: Yanai J, editor. Neurobehavioral teratology. Amsterdam: Elsevier, 1984: 315-29
63. 63. Spigset O, Hagg S. Excretion of psychotropic drugs into breast milk: pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9 (2): 111-34
64. 64. Kurz H, Michels H, Stickel HH. Differences in the binding of drugs to plasma proteins from newborn and adult man: II. Eur J Clin Pharmacol 1977; 11 (6): 469-72
65. 65. Morselli PL, Franco-Morseli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet 1980; 5 (6): 485-527
66. 66. Sereni F, Mandelli M, Principi N, et al. Induction of drug metabolizing enzyme activities in the human fetus and in the newborn infant. Enzyme 1973; 15 (1): 318-29
67. 67. Aranda JV, MacLeod SM, Renton KW, et al. Hepatic microsomal drug oxidation and electron transport in newborn infants, J Pediatr 1974; 85 (4): 534-42
68. 68. Mollgard K, Saunders NR. The development of the human blood-brain and blood-CSF barriers. Neuropathol Appl Neurobiol 1986; 12: 337-58
69. 69. Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet 1989; 17 Suppl. 1: 13-28
70. 70. Kellogg CK. Benzodiazepines: influence on the developing brain. In: Boer GJ, Feenstra MGP, Mirmiran M, et al., editors. Progress in brain research. New York (NY): Elsevier, 1988: 207-28
71. 71. Insel TR. The development of brain and behavior. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, Ltd, 1995: 683-94
72. 72. Nestler EJ, Duman RS. Intracellular messenger pathways as mediators of neural plasticity. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, Ltd, 1995: 695-704
73. 73. O'Donoghue JL. Defining what is neurotoxic. In: Weiss B, O'Donoghue J, editors. Neurobehavioral toxicity: analysis and interpretation. New York (NY): Raven Press, 1994: 19-33
74. 74. Spear LP. Assessment of the effects of developmental toxicants: pharmacological and stress vulnerability of offspring. In: Wetherington CL, Smeriglio VL, Finnegan LP, editors. NIDA Research Monograph Series: behavioral studies of drug-exposed offspring: methodological issues in human and animal research. Rockville (MD): National Institute on Drug Abuse, 1996: 125-45
75. 75. Vorhees CV, Brunner RI, Butcher RE. Psychotropic drugs as behavioral teratogens. Science 1979; 205: 1220-5
76. 76. Boer GJ, Swaab DF. Neuropeptide effects on brain development to be expected from behavioral teratology. Peptides 1985; 6 (2): 21-8
77. 77. Kellogg CK, Taylor MK, Rodriguez-Zafra M, et al. Altered stressor-induced changes in GABA A receptor function the cerebral cortex of adult rats exposed in utero to diazepam. Pharmacol Biochem Behav 1993; 44 (2): 267-73
78. 78. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996; 153 (2): 151-62
79. 79. Braestrup C, Nielsen M. Ontogenetic development of benzodiazepine receptors in the brain. Brain Res 1978; 147: 170-3
80. 80. Hebebrand J, Hofmann D, Reichelt R, el al. Early ontogeny of the central benzodiazepine receptor in human embryos and fetuses. Life Sci 1988; 43 (25): 2127-36
81. 81. Nomura Y, Tanaka Y, Segawa T. Influences of sodium, ouabain and tricyclic antidepressant drugs on L-[3H]norepinephrine uptake into synaptosomal fractions of developing rat brain. Jpn J Pharmacol 1978; 28 (3): 501-4
82. 82. Moody CA, Robinson SR, Spear LP, et al. Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations. Pharmacol Biochem Behav 1993; 44 (4): 843-50
83. 83. Mercado R, Hernandez R-J. A molecular recognizing system of serotonin in rat fetal axonal growth cones: uptake and high affinity binding. Brain Res Dev Brain Res 1992; 69: 133-7
84. 84. Mallorga P, Hamburg M, Tallman JF, et al. Ontogenetic changes in GABA modulation of brain benzodiazepine binding. Neuropharmacology 1980; 19: 405-8
85. 85. Simmons RD, Miller RK, Kellogg CK. Prenatal exposure to diazepam alters central and peripheral responses to stress in adult rat offspring. Brain Res 1984; 307: 39-46
86. 86. Deutch AY, Young CD. A model of the stress-induced activation of prefrontal cortical dopamine systems: coping and the development of post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to PTSD. Philadelphia (PA): Lippincott-Raven, 1995: 163-75
87. 87. Mirmiran M, Feenstra MGP, Dijcks FA, et al. Functional deprivation of noradrenaline neurotransmission: effects of clonidine on brain development. In: Boer GJ, Feenstra MGP, Mirmiran M, et al., editors. Progress in brain research. New York (NY): Elsevier, 1988: 159-72
88. 88. Armitage SG. The effect of barbiturates in the behavior of rat offspring as measured on learning and reasoning situations. J Comp Physiol Psychol 1952; 45: 146-9
89. 89. Ordy JM, Samorjaski T, Collins RL, et al. Prenatal chlorpromazine effects on liver, survival and behavior of mice offspring. J Pharmacol Exp Ther 1966; 151 (1): 110-15
90. 90. Werboff J, Gottlieb JS, Dembicki EL, et al. Postnatal effect of antidepressant drugs administered during gestation. Exp Neurol 1961; 3: 542-4
91. 91. De Ceballos ML, Benedi A, De Felipe C, et al. Prenatal exposure of rats to antidepressants enhances agonist affinity of brain dopamine receptors and dopamine-mediated behavior. Eur J Pharmacol 1985; 116: 257-62
92. 92. Montero D, Ceballos ML, Del Rio J. Down-regulation of 3H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sci 1990; 46: 1619-26
93. 93. Vorhees CV, Acuff-Smith KD, Schilling MA, et al. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994; 23: 194-205
94. 94. Cabrera-Vera TM, Garcia F, Pinto W, et al. Effect of prenatal fluoxetine (prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther 1997; 280 (1): 138-45
95. 95. Gai N, Grimm VE. The effect of prenatal exposure to diazepam on aspects of postnatal development and behavior in rats. Psychopharmacology 1982; 78 (3): 225-9
96. 96. Singh Y, Jaiswal AK, Singh M, et al. Behavioral effects of prenatal diazepam administration on anxiety patterns in rats. Indian J Exp Biol 1996; 34 (11): 1095-9
97. A receptor function. Neuropharmaoclogy 1991; 30 (1): 53-8
98. 98. Koff JM, Miller LG. Prenatal lorazepam exposure: 4. Persistent alterations in pentylenetetrazole-induced seizure threshold and GABA-dependent chloride uptake after prenatal lorazepam exposure. Pharmacol Biochem Behav 1995; 51 (4): 721-4
99. 99. Scalzo FM, Ali SF, Holson RR. Behavioral effects of prenatal haloperidol exposure. Pharmacol Biochem Behav 1989; 34 (4): 727-31
100. 100. Robertson RT, Majka JA, Peter CP, et al. Effects of prenatal exposure to chlorpromazine on postnatal development and behavior of rats. Toxicol Appl Pharmacol 1980; 53: 541-9
101. 101. Vorhees CV, Minck DR. Long-term effects of prenatal phenytoin exposure on offspring behavior in rats. Neurotoxicol Teratol 1989; 11 (3): 295-305
102. 102. Livezey GT, Rayburn WR, Smith CV. Prenatal exposure to phenobarbital and quantifiable alterations in the electroencephalogram of adult rat offspring. Am J Obstet Gynecol 1992; 167: 1611-5
103. 103. Zahalka EH, Rehavi M, Newman ME, et al. Alterations in hippocampal hemicholinium-3 binding and related behavioural and biochemical changes after prenatal phenobarbitone exposure. Psychopharmacology 1995; 122 (1): 44-50
104. 104. Tsutsumi S, Akaike M, Ohno H, et al. Learning/memory impairments in rat offspring prenatally exposed to phenytoin. Neurotoxicol Teratol 1998; 20 (2): 123-32
105. 105. Laviola G. Mouse models of emotional postpartum disorders. Ann 1st Super Sanita 1993; 29 (1): 153-62
106. 106. Vogel G, Neill D, Hagler M, et al. A new animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 1990; 14: 85-91
107. 107. Hilakivi LA, Hilakivi I. Increased adult behavioral 'despair' in rats neonatally exposed to desipramine or zimeldine: an animal model of depression? Pharmacol Biochem Behav 1987; 28: 367-9
108. 108. Sams-Dodd F, Lipska BK. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 1997; 132 (3): 303-10
109. 109. Spear LP. Neurobehavioral assessment during the early postnatal period. Neurotoxicol Teratol 1990; 12: 489-95
110. 110. Dallemagne G, Weiss B. Altered adult behavior of mice following postnatal treatment with haloperidol. Pharmacol Biochem Behav 1982; 16 (5): 761-7
111. 111. Velazquez-Moctezuma J, Ruiz OD. Neonatal treatment with clomipramine increased immobility in the forced swim test: an attribute of animal models of depression. Pharmacol Biochem Behav 1992; 42: 737-9
112. 112. Hilakivi I. Early postnatal antidepressant treatment and juvenile stereotyped behaviour in rats. Eur J Pharmacol 1994; 271: 223-6
113. 113. Benesova O, Petova J, Vinsova N. Perinatal distress and brain development. Prague: Avicenum, 1980
114. 114. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8 (6): 461-75
115. 115. Jason KM, Cooper TB, Friedman E. Prenatal exposure to imipramine alters early behavioral development and beta adrenergic receptors in rats. J Pharmacol Exp Ther 1981; 217 (2): 461-6
116. 116. Kurata K, Kurachi M, Tanii Y. Distribution of clomipramine in various brain regions of rats under steady-state serum concentrations. Psychopharmacology 1988; 95: 167-70
117. 117. Pohland R, Byrd TK, Hamilton M, et al. Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989; 98: 198-205
118. 118. Simar MR, Johnson VA. Neonatal effects of lactational exposure to antidepressant drugs in rats [abstract]. Society for Neuroscience 27th Annual Meeting; 1997 Oct 25-30; New Orleans (LA), 1111
119. 119. Broitman ST, Donoso AO. Effects of chronic imipramine and clomipramine oral administration on maternal behavior and litter development. Psychopharmacology 1978; 56: 93-101
120. 120. Frieder B, Epstein S, Grimm VE. The effects of exposure to diazepam during various stages of gestation or during lactation on the development and behavior of rat pups. Psychopharmacology 1984; 83: 51-5
121. 121. Shibuya T, Watanabe Y, Hill HF, et al. Developmental alterations in maturing rats caused by chronic prenatal and postnatal diazepam treatments. Jpn J Pharmacol 1986; 40 (1): 21 -9
122. A receptor function: influence on adaptive responses. In: Thadani P, editor. Biological mechanisms and perinatal exposure to abused drugs. Rockville (MD): National Institute on Drug Abuse, 1995: 202-26
123. 123. Nasarallah HA. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin North Am 1993; 16 (2): 269-77
124. 124. Wolf SS, Hyde T, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurol Neurosurg 1993; 6 (1): 86-92
125. 125. Levy F, Barr C, Sunohara G. Directions of aetiologic research on attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1998; 32 (1): 97-103
126. 126. Food and Drug Administration. Pregnancy categories. Fed Regist 1979; 44 (124): 37434
127. 127. Crowe TK, Deitz JC, Bennett FC. The relationship between the Bayley Scales of Infant Development and preschool gross motor and cognitive performance. Am J Occupat Ther 1987; 41 (6): 374-8
128. 128. Aylward GP. Conceptual issues in developmental screening and assessment. J Devel Behav Pediatr 1997; 18 (5): 340-9
129. 129. Harris SR, Langkamp DL. Predictive value of the Bayley mental scale in the early detection of cognitive delays in high-risk infants. Perinatology 1994; 14 (4): 275-9
130. 130. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci 1997; 22 (3): 192-6
131. 131. Cohen LS, Rosenbaum J. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998; 59 Suppl. 2: 18-28
132. 132. Chisholm CA, Kuller JA. A guide to the safety of CNS-active agents during breastfeeding. Drug Saf 1997; 17 (2): 127-42
133. 133. Goldberg HL, Nissim R. Psychotropic drugs in pregnancy and lactation. Int J Psychiatr Med 1994; 24 (2); 129-49
134. 134. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 1998; 59 Suppl. 2: 29-33
135. 135. Nonacs R, Cohen LS. Postpartum mood disorders: diagnosis and treatment guidelines. J Clin Psychiatry 1998; 59 Suppl. 2: 34-40
136. 136. Chelmow D, Halfin V. Pregnancy complicated by obsessive-compulsive disorder. J Matern Fetal Med 1997; 6: 31-4
137. 137. Briggs GG, Samson JH, Ambrose PJ, et al. Excretion of bupropion in breast milk. Ann Pharmacother 1993; 27: 431-3
138. 138. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European network of teratology information services. Reprod Toxicol 1996; 10 (4): 285-94
139. 139. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21 (2): 157-71
140. 140. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-62
141. 141. Gotlib IH, Whiffen VE, Mount JH, et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clinl Psychol 1989; 57: 269-74
142. 142. Hopkins J, Marcus M, Campbell SB. Postpartum depression: a critical review. Psychol Bull 1984; 95 (3): 498-515
143. 143. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153 (9): 1132-7
144. 144. Buist A, Janson H. Effect of exposure to dothiepin and northiaden in breast milk on child development. Br J Psychiatry 1995; 167 (3): 370-3
145. 145. Yoshida K, Smith B, Kumar CR. Fluvoxamine in breast-milk and infant development. Br J Clin Pharmacol 1997; 44: 210-1
146. 146. Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43: 225-37
147. 147. Erickson SH, Smith GH, Heidrich F. Tricyclics and breast feeding [letter]. Am J Psychiatry 1979; 136 (11): 1483-4
148. 148. Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. Am J Psychiatry 1980; 137: 855-6
149. 149. Ilet KF, Lebedevs TH, Wojnar H, et al. The excretion of dothiepin and its primary metabolites in breast milk. Br J Clin Pharmacol 1992; 33: 635-9
150. 150. Wisner KL. Nortriptyline and its hydroxymetabolites in breast-feeding mothers and newborns. Psychopharmacol Bull 1997; 33 (2): 249-51
151. 151. Stancer HC, Reed KL. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum. Am J Psychiatry 1986; 143 (12): 1597-600
152. 152. Mammen O, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58 (3): 100-3
153. 153. Ploman L, Persson B. On the transfer of barbiturates to the fetus and their accumulation in some of its vital organs. J Obstet Gynaecol 1957; 64: 706-11
154. 154. Mandelli M, Morselli PL, Nordio S, et al. Placental transfer to diazepam and its disposition in the newborn. Clin Pharmacol Ther 1975; 17 (5): 564-72
155. 155. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. BMJ 1981; 282: 1106-8
156. 156. Hartz S, Heinonen OP, Shapiro S, et al. Antenatal exposure to meprobamate, and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975; 292: 726-8
157. 157. Laegreid L, Hagberg G, Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines - a prospective study. Neuropediatrics 1992; 23: 60-7
158. 158. Viggedal G, Hagberg BS, Laegreid L, et al. Mental development in late infancy after prenatal exposure to benzodiazepines - a prospective study. J Child Psychol Psychiatr 1993; 34 (3): 295-305
159. 159. Kerns LL. Treatment of mental disorders in pregnancy: a review of psychotropic drug risks and benefits. J Nerv Ment Dis 1986; 174 (11): 652-9
160. 160. Sitland-Marken PA, Rickman LA, Wells BG, et al. Pharmacologic management of acute mania in pregnancy. J Clin Psychopharmacol 1989; 9 (2): 78-87
161. 161. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54: 193-7
162. 162. Morrell P, Sutherland GR, Baumah PK, et al. Lithium toxicity in a neonate. Arch Dis Child 1983; 58 (7): 539-41
163. 163. Sykes PA. Quarre V, Alexander FW. Lithium carbonate and breast feeding. BMJ 1976; 2 (6047): 1299
164. 164. Weinstein M, Goldfield M. Lithium carbonate treatment during pregnancy. Dis Nerv Syst 1969; 30: 828-62
165. 165. Skausig OB, Schou M. Breast feeding during lithium treatment. Ugeskr Laeger 1977; 139: 400-1
166. 166. Kris EB. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 1965; 7 (12): 785-9
167. 167. Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128: 486-8
168. 168. Tarsy D, Baldessarini RJ. Movement disorders induced by psychotherapeutic agents. Clinical features, pathophysiology and management. In: Shah NS, Donald AG, editors. Movement disorders. New York (NY): Plenum Press, 1986: 365-89
169. 169. O'Connor M, Johnson GH, James DI. Intrauterine effect of phenothiazines. Med J Aust 1981; 1 (8): 416-7
170. 170. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol 1989; 9 (2): 170-2
171. 171. Whalley LJ, Blain PG, Prime JK. Haloperidol secreted in breast milk. BMJ 1981; 282: 1746-7
172. 172. Yoshida K, Smith B, Craggs M, et al. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med 1998; 28: 81-91
173. 173. Jager-Roman E, Deichl A, Jokob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108 (6): 997-1004
174. 174. Buehler BA, Rao V, Finnell RH. Biochemical and molecular teratology of fetal hydantion syndrome. Neurol Clin 1994; 12 (4): 741-8
175. 175. Fisher JE, Vorhees CV. Developmental toxicity of antiepileptic drugs: relationship to postnatal dysfunction. Pharmacol Res 1992; 26 (3): 207-21
176. 176. Samren EB, Van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38 (9): 981-90
177. 177. Dessens AB, Boer K, Koppe JG, et al. Studies on long-lasting consequences of prenatal exposure to anticonvulsant drugs. Acta Paediatr Suppl 1994; 404: 54-64
178. 178. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; 7 (1): 272-5
179. 179. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32 (5): 403-14
180. 180. Lindhout D, Omtzigt JGC. Teralogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35 (4): S19-28
181. 181. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661-6
182. 182. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271 (10): 767-70
183. 183. Vanoverloop D, Schnell RR, Harvey EA, et al. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992; 14 (5): 329-35
184. 184. van der Pol MC, Hadders-Algra M, Huisjes HJ, et al. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am J Obstet Gynecol 1991; 164: 121-8
185. 185. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75 (6): 517-20
186. 186. Koch S, Jager-Roman E, Losche G, et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr 1996; 84: 736-9
187. 187. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19 (3): 473-81
188. 188. Ardinger HH, Atkin JF, Blackson RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29 (1): 171-85
189. 189. Adams J, Vorhees CV, Middaugh LD. Developmental neurotoxicity of unticonvulsants: human and animal evidence on phenytoin. Neurotoxicol Teratol 1990; 12: 203-14
190. 190. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274 (19): 1518-25
191. 191. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38 (9): 1039-41
192. 192. Zahn CA, Morrell MJ, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998; 51 (4): 949-56
193. 193. Stuart S, O'Hara MW. Treatment of postpartum depression with interpersonal psychotherapy. Arch Gen Psychiatry 1995; 52 (1): 75-6
194. 194. Gruen DS. A group psychotherapy approach to postpartum depression. Int J Group Psychother 1993; 43 (2): 191-203
195. 195. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997; 29 (314): 932-6
196. 196. Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy. Psychopharmacol Bull 1998; 34 (3): 339-46
197. 197. Stuart S, O'Hara M, Blehar MC. Mental disorders associated with childbearing: report of the biennial meeting of the Marce Society. Psychopharmacol Bull 1998; 34 (3): 333-8
198. 198. Carpenter WTJ, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147 (9): 1138-48
199. 199. Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983; 46 (8): 751-5
200. 200. Morrell MJ. Guidelines for the care of women with epilepsy. Neurology 1998; 51 (5 Suppl. 4): S21-7
201. 201. Chang SI, McAuley JW. Pharmacotherapeutic issues for women of childbearing age with epilepsy. Ann Pharmacother 1998; 32 (7-8): 794-801
202. 202. Kaneko S. Pregnancy and quality of life in women with epilepsy. Clin Ther 1998; 20 Suppl. A: A30-47
203. 203. Swartjes JM, Geijn HP. Pregnancy and epilepsy. Eur J Obstet Gynecol Reprod Biol 1998; 79 (1): 3-11
204. 204. Johnson EM, Newman LM, Schmidt RR. Postnatal effects of prenatal insult. Risk Anal 1988; 8 (1): 35-44
205. 205. Meaney MJ, Aitken DH, van Berkel C, et al. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science 1980; 12: 766-8
206. 206. Casaer P, De Vries L, Marlow N. Prenatal and perinatal risk factors for psychosocial development. In: Rutter M, Casaer P, editors. Biological risk factors for psychosocial disorders. Cambridge: Cambridge University Press, 1991: 50-66
207. 207. NAREP. North American Registry for Epilepsy and Pregnancy, a unique public/private partnership of health surveillance. Epilepsia 1998; 39 (7): 793-8
208. 208. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338 (16): 1128-37
209. 209. Gaylor DW, Razzaghi M. Process of building biologically based dose-response models for developmental defects. Teratology 1992; 46: 573-81
210. 210. Vorhees CV. Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins. Drug Chem Toxicol 1997; 20 (4): 387-99
211. 211. Sobotka TJ, Ekelman KB, Slikker W, et al. Food and drug administration proposed guidelines for neurotoxicological testing of food chemical. Neurotoxicology 1996; 17 (3-4): 825-36
212. 212. Vorhees CV. Developmental neurotoxicity induced by therapeutic and illicit drugs. Environ Health Perspect 1994; 102: 145-53
213. 213. Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safely of breast-feeding. J Psychopharmacol 1999; 13 (1): 64-80